Statements (102)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:academic_advisor |
leading scientists
|
| gptkbp:acquisition |
Acquired by a larger pharmaceutical company
|
| gptkbp:awards |
industry recognition
|
| gptkbp:business_model |
collaborative development
ethical standards |
| gptkbp:ceo |
gptkb:Bill_Newell
|
| gptkbp:clinical_trial |
patient recruitment
ongoing studies multiple stages new methodologies efficient processes patient-centered approach high success rates positive outcomes various phases innovative methodologies comprehensive studies Phase 1 trials adaptive designs rigorous oversight successful results Sutro's lead product candidate |
| gptkbp:clinical_trial_outcomes_analysis |
thorough evaluations
|
| gptkbp:clinical_trial_results_analysis |
data-driven insights
|
| gptkbp:clinical_trial_results_reporting |
transparent communication
|
| gptkbp:collaboration |
academic institutions
|
| gptkbp:collaborations |
academic partnerships
cross-industry partnerships |
| gptkbp:collaborator |
biopharmaceutical companies
|
| gptkbp:community_engagement |
local initiatives
|
| gptkbp:community_support |
local partnerships
|
| gptkbp:employees |
approximately 100
|
| gptkbp:financial_performance |
growing revenue
|
| gptkbp:financial_support |
venture capital funding
|
| gptkbp:focus |
therapeutics
|
| gptkbp:founded |
gptkb:2003
|
| gptkbp:founder |
gptkb:Bill_Newell
|
| gptkbp:funding |
public offerings
grants and investments |
| gptkbp:global_presence |
international collaborations
|
| gptkbp:has_research_center |
state-of-the-art labs
|
| gptkbp:head_of_state |
strategic initiatives
|
| gptkbp:headcount |
growing workforce
|
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| gptkbp:healthcare |
cutting-edge research
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sutro Biopharma, Inc.
|
| gptkbp:impact |
significant contributions
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:initiatives |
new projects
|
| gptkbp:instruction_set |
multiple drug candidates
|
| gptkbp:invention |
numerous patents filed
|
| gptkbp:investment |
high demand
unique offerings regular reports Venture capital firms transparent communication |
| gptkbp:investment_focus |
oncology
|
| gptkbp:is_a_platform_for |
proprietary technology
|
| gptkbp:leadership |
experienced management team
|
| gptkbp:market |
strategic planning
industry analysis |
| gptkbp:market_position |
leading innovator
|
| gptkbp:marketing_strategy |
targeted therapies
|
| gptkbp:mission |
develop innovative therapies
|
| gptkbp:partnership |
gptkb:Bristol-Myers_Squibb
gptkb:Celgene strategic collaborations |
| gptkbp:partnerships |
collaborative research
strategic alliances |
| gptkbp:product |
innovative solutions
|
| gptkbp:products |
protein therapeutics
|
| gptkbp:publications |
peer-reviewed articles
|
| gptkbp:regulatory_compliance |
strict adherence
FDA approval process |
| gptkbp:research |
ongoing investigations
|
| gptkbp:research_and_development |
significant investment
|
| gptkbp:research_areas |
advanced therapies
multiple indications focused studies |
| gptkbp:research_focus |
biologics
cancer therapies |
| gptkbp:research_output |
measurable results
|
| gptkbp:safety |
priority focus
|
| gptkbp:scientific_goals |
long-term objectives
|
| gptkbp:stock_exchange |
publicly traded
|
| gptkbp:stock_symbol |
STRO
|
| gptkbp:strategic_goals |
expand product pipeline
|
| gptkbp:sustainability |
environmental practices
|
| gptkbp:technology |
cell-free protein synthesis
|
| gptkbp:therapeutic_advancements |
breakthrough therapies
|
| gptkbp:therapeutic_development_strategy |
focused approach
|
| gptkbp:therapeutic_pipeline |
diverse candidates
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
promising results
|
| gptkbp:trends |
emerging therapies
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:type_of_care |
focus on patient needs
|
| gptkbp:vision |
transforming patient care
|
| gptkbp:website |
www.sutrobio.com
|
| gptkbp:bfsParent |
gptkb:Ariad_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|